Yahoo Web Search

Search results

1. www.amgen.com › newsroom › press-releasesNews | Amgen

   www.amgen.com › newsroom › press-releases

   • Cached

   AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024. 05.09.2024. AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE. 05.02.2024. AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS. 05.01.2024. AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024.

   • AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC

     THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen...

   • Press Releases | Amgen Inc.

     AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL...

   • AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

     THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022...

   • AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022

     Phase 1 Results Showed up to 14.5% Reduction in Body Weight...

2. Top Stories

   • 
     The Motley Fool on MSN.com

     Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?

     Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

     22 hours ago

   • 

     YAHOO!Finance

     It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This Year

     2 days ago

   • 

     Law

     In the Wake of 'Amgen v. Sanofi,' the USPTO Clarifies the Patent Enablement Requirement

     3 days ago

   • 

     Seeking Alpha

     Amgen Stock: Poised To Break Out (Technical Analysis)

     6 days ago

   • Zacks.com on MSN.com

     Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

     2 weeks ago

   View all

3. People also ask

   How much does Amgen Inc's CEO make a year?

   • At the time of writing, our data shows that Amgen Inc. has a market capitalization of US$164b, and reported total annual CEO compensation of US$23m for the year to December 2023. That's a fairly small increase of 5.8% over the previous year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$1.8m.

   It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge P…

   finance.yahoo.com/news/unlikely-amgen-inc-nasdaq-amgn-134450327.html

   See all results for this question

   Is Amgen (AMGN) a good stock to buy?

   • Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this world's largest biotech drugmaker have returned +20.8%, compared to the Zacks S&P 500 composite's +5% change.

   Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting o…

   www.msn.com/en-us/money/markets/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it/ar-BB1mvtAa

   See all results for this question

   How much money does Amgen spend on R&D?

   • Amgen’s main engine for growth is its generous R&D funding. As seen in the second chart below, AMGN’s current R&D budget exceeds $5B on a TTM basis, translating into about 17.2% of its total sales.

   Amgen Stock: Poised To Break Out (Technical Analysis)

   seekingalpha.com/article/4694852-amgen-stock-poised-to-break-out-technical-analysis

   See all results for this question

   How did Amgen perform in the last quarter?

   • Amgen reported revenues of $7.45 billion in the last reported quarter, representing a year-over-year change of +22%. EPS of $3.96 for the same period compares with $3.98 a year ago. Compared to the Zacks Consensus Estimate of $7.38 billion, the reported revenues represent a surprise of +0.93%.

   Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting o…

   www.msn.com/en-us/money/markets/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it/ar-BB1mvtAa

   See all results for this question

4. finance.yahoo.com › quote › AMGNAmgen Inc. (AMGN) Latest Stock News & Headlines - Yahoo Finance

   finance.yahoo.com › quote › AMGN

   • Cached

   3-Year. +34.13%. +27.64%. Get the latest Amgen Inc. (AMGN) stock news and headlines to help you in your trading and investing decisions.

5. www.amgen.com › newsroom › press-releasesAMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC

   www.amgen.com › newsroom › press-releases

   • Cached

   THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

6. investors.amgen.com › news-and-events › press-releasesPress Releases | Amgen Inc.

   investors.amgen.com › news-and-events › press-releases

   • Cached

   Apr 29, 2024 · AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE. NEWS RELEASE 05.02.2024. AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS. NEWS RELEASE 05.01.2024. AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024. NEWS RELEASE 04.29.2024.

7. www.amgen.com › newsroom › press-releasesAMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

   www.amgen.com › newsroom › press-releases

   • Cached

   Aug 4, 2022 · THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive ...

8. www.reuters.com › markets › dealsAmgen completes $27.8 billion Horizon Therapeutics deal

   www.reuters.com › markets › deals

   Oct 6, 2023 · United States of America. Follow. Oct 6 (Reuters) - Amgen (AMGN.O) said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics (HZNP.O) after it received the go-ahead...

9. www.amgen.com › newsroom › press-releasesAMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022

   www.amgen.com › newsroom › press-releases

   • Cached

   Dec 1, 2022 · Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks. Initiating Phase 2 Study in Early 2023. THOUSAND OAKS, Calif., Dec. 1, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist ...